Statement from Michael Sapienza, CEO of the Colon Cancer Alliance, on FDA Approval of VARUBI Intravenous Administration
October 26, 2017 (WASHINGTON)–VARUBI, a highly anticipated treatment for colorectal patients who suffer from delayed chemotherapy-induced nausea, has been approved by the Food and Drug Administration for delivery via one-time intravenous administration. This new way to administer VARUBI provides healthcare providers with flexibility to treat patients in a more individualized manner.
VARUBI addresses delayed nausea that can arrive 24 to 120 hours after the start of chemotherapy. If nausea is not managed aggressively, it can lead to weight loss, dehydration, and hospitalization. Quality-of-life issues are incredibly important for patients and families dealing with colorectal cancer and chemotherapy. The approval of VARUBI is good step forward in addresses some of these concerns.
For more information about VARUBI, please access:
https://globenewswire.com/news-release/2017/10/25/1153687/0/en/TESARO-Announces-U-S-FDA-Approval-of-VARUBI-IV-for-Delayed-Nausea-and-Vomiting-Associated-With-Cancer-Chemotherapy.html
Top resources

Champions of the Young Adult Cancers Act Push for Progress at National Blue Hope Bash
At the 2026 Blue Hope Bash, the Colorectal Cancer Alliance honored the late Asal Sayas and raised $1.5 million to help end colorectal cancer in young adults.

Colorectal Cancer Alliance Rallies Support for Bipartisan Bill to Create First National Plan on Young Adult Cancers
A new bipartisan bill would create the first national plan on cancers in adults under 50. Join the Colorectal Cancer Alliance to help pass it.

In Shawn’s corner: Stepping into the ring to end CRC
Shawn has lived with Crohn’s disease since age 10, a condition that raises his risk of colorectal cancer. He’s stepping into the ring with Haymakers for Hope to help end this disease, and he wants you in his corner.




